Cargando…
The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer
Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton’s tyrosine kinase (BTK) inhibitor LFM-A13 on the viability and tumour development of breast cance...
Autores principales: | Rozkiewicz, Dariusz, Hermanowicz, Justyna Magdalena, Tankiewicz-Kwedlo, Anna, Sieklucka, Beata, Pawlak, Krystyna, Czarnomysy, Robert, Bielawski, Krzysztof, Surazynski, Arkadiusz, Kalafut, Joanna, Przybyszewska, Alicja, Koda, Mariusz, Jakubowska, Katarzyna, Rivero-Muller, Adolfo, Pawlak, Dariusz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717683/ https://www.ncbi.nlm.nih.gov/pubmed/32912025 http://dx.doi.org/10.1080/14756366.2020.1818738 |
Ejemplares similares
-
Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer
por: Tankiewicz-Kwedlo, Anna, et al.
Publicado: (2018) -
Simultaneous use of erythropoietin and LFM‐A13 as a new therapeutic approach for colorectal cancer
por: Tankiewicz‐Kwedlo, Anna, et al.
Publicado: (2018) -
Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer
por: Hermanowicz, Justyna Magdalena, et al.
Publicado: (2021) -
Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts
por: Tankiewicz-Kwedlo, A., et al.
Publicado: (2016) -
MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer
por: Hermanowicz, Justyna Magdalena, et al.
Publicado: (2021)